Mevion Medical Systems
RELATED CONTENT
February 28, 2014 — A 6-year-old with a highly malignant medulloblastoma brain tumor is the first pediatric patient treated using the Mevion S250 proton therapy system at Washington University Medical Center in St. Louis. This milestone event marks the first pediatric case ever treated on the world’s only single-room proton therapy system.
February 28, 2014 
A patient with a rare type of cancer (chondrosarcoma) at the base of the skull has become the first person in the world to receive proton therapy using the Mevion S250 proton therapy system from Mevion Medical Systems Inc. of Littleton, Mass.
December 24, 2013 
Mevion Medical Systems Inc. has secured $55 million to accelerate the deployment of its revolutionary Mevion S250 Proton Therapy System. The funds were raised from existing equity investors, including Caxton Heath Life Sciences, ProQuest Investments, Venrock and CHL Medical Partners, as well as from debt financing provided by Life Sciences Alternative Funding LLC (LSAF).
August 15, 2013 
Mevion Medical Systems has delivered the superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system under installation at the Peggy and Charles Stephenson Cancer Center at the University of Oklahoma.
June 03, 2013 At ASTRO 2012, Mevion featured its compact Mevion S250 Proton Therapy System, which has a footprint comparable to ...
November 20, 2012 
Mevion Medical Systems announced the delivery of its fifth TriNiobium Core proton accelerator, the powerful proton source that is at the center of the revolutionary Mevion S250 Proton Therapy System. This accelerator will be delivered early next year to First Coast Oncology in Jacksonville, Fla. All 2013 and early 2014 Mevion S250 deliveries are already in the manufacturing stage.
November 02, 2012 July 24, 2012 — Mevion Medical Systems announced today that it has delivered the superconducting synchrocyclotron for the Mevion S250 Proton Therapy System currently under installation at Robert Wood Johnson University Hospital in New Brunswick, N.J., the flagship cancer hospital of The Cancer Institute of New Jersey and the principle teaching hospital of UMDNJ-Robert Wood Johnson Medical School.
July 24, 2012 
June 11, 2012 — Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced that it has received FDA 510(k) clearance for its Mevion S250 Proton Therapy System. The Mevion S250 is a first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment advantages and capabilities of complex, large, and costly proton therapy systems but with higher patient throughput, a significantly reduced footprint, improved reliability, and lower implementation and operational costs. The Mevion S250 delivers precise and intense proton beams that physicians can use to treat tumors and lesions or any other condition where radiotherapy is indicated.
June 11, 2012 
March 14, 2012 - Mevion Medical Systems announced today it received CE mark certification for the Mevion S250 Proton Therapy System. This important commercial milestone indicates that Mevion has completed its development in compliance with the European Union's Medical Device Directive. The CE Marking allows the MEVION S250 to be marketed, sold, and installed in the European
Union and in any country recognizing CE mark approval.
March 16, 2012 
January 26, 2012 — Mevion Medical Systems announced that it has closed a $45 million investment from ProQuest Investments and its existing investors, including Caxton Heath Life Sciences, Venrock and CHL Medical Partners. Mevion is the manufacturer of the Mevion S250 proton therapy system. The capital will be used to accelerate the manufacturing and worldwide deployment of the Mevion S250.
January 26, 2012